Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (8) | Ignore Thread Prev | Next
Author: SarahGen Big gold star, 5000 posts Top Favorite Fools Old School Fool Ticker Guide Supernova Odyssey 1
Mission Team Member CAPS All Star Global Fool SN Explorer 1 Mission Team Member Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 24983  
Subject: Re: OPTR - SarahGen Date: 12/29/2009 8:34 PM
Post New | Post Reply | Reply Later | Create Poll Report this Post | Recommend it!
Recommendations: 1
Par has exclusive rights to market, sell and distribute the product in the U.S. and Canada. Par will pay Optimer a royalty on sales of the product....

ignore this. That news release is from 2005.

In 2007, Optimer bought some of the rights back. According to the last Annual Report (filed in March 2009):
Following our repurchase of certain development and commercialization rights from Par Pharmaceutical, Inc. in February 2007, we hold worldwide rights to fidaxomicin.
http://sec.gov/Archives/edgar/data/1142576/00011046590901713...

Further info on Par from that annual report:
We hold worldwide rights to fidaxomicin. In February 2007, we elected to exercise our right under a prospective buy-back agreement to repurchase Par Pharmaceutical, Inc.’s rights to develop and commercialize fidaxomicin in North America and Israel. We paid Par a one-time $20.0 million termination fee. We are obligated to pay Par a one-time $5.0 million milestone payment, a 5% royalty on net sales by us or our affiliates of fidaxomicin in North America and Israel, and a 1.5% royalty on net sales by us or our affiliates of fidaxomicin in the rest of the world. In addition, in the event we license our right to market fidaxomicin in the rest of the world, we will be required to pay Par a 6.25% royalty on net revenues we receive related to fidaxomicin. We are obligated to pay each of these royalties, if any, on a country-by-country basis for seven years commencing on the applicable commercial launch in each such country. We intend to seek one or more partners for the commercialization of fidaxomicin outside North America.

Sarah
Post New | Post Reply | Reply Later | Create Poll Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (8) | Ignore Thread Prev | Next

Announcements

Foolanthropy 2014!
By working with young, first-time moms, Nurse-Family Partnership is able to truly change lives – for generations to come.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Post of the Day:
Macro Economics

Looking at Currency Ratios
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement